

CITATION REPORT

List of articles citing

ATM and ATR as therapeutic targets in cancer

DOI: 10.1016/j.pharmthera.2014.12.001

Pharmacology & Therapeutics, 2015, 149, 124-38.

Source: <https://exaly.com/paper-pdf/62779986/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
441	Ailanthone Inhibits Huh7 Cancer Cell Growth via Cell Cycle Arrest and Apoptosis In Vitro and In Vivo. 2015 , 5, 16185		63
440	Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. 2015 , 27, 475-81		15
439	DNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of Cancer. 2015 , 5, 3204-59		62
438	MYC as therapeutic target in leukemia and lymphoma. 2015 , 75		2
437	Characterization and identification of hidden rare variants in the human genome. 2015 , 16, 340		17
436	HSP90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas. 2015 , 365, 211-22		30
435	Precision medicine for metastatic breast cancer--limitations and solutions. 2015 , 12, 693-704		201
434	Nrf2 facilitates repair of radiation induced DNA damage through homologous recombination repair pathway in a ROS independent manner in cancer cells. 2015 , 779, 33-45		65
433	Cell cycle gene expression networks discovered using systems biology: Significance in carcinogenesis. 2015 , 230, 2533-42		11
432	ATM rs189037 (G>A) polymorphism and risk of lung cancer and head and neck cancer: A meta-analysis. 2015 , 6, 42-8		12
431	Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. 2015 , 5, 1137-54		436
430	Molecular Pathways: Targeting ATR in Cancer Therapy. 2015 , 21, 4780-5		151
429	ATR Plays a Direct Antiapoptotic Role at Mitochondria, which Is Regulated by Prolyl Isomerase Pin1. 2015 , 60, 35-46		42
428	Kinase inhibitors as potential agents in the treatment of multiple myeloma. 2016 , 7, 81926-81968		13
427	Cell-free Xenopus egg extracts for studying DNA damage response pathways. 2016 , 60, 229-236		18
426	(), could it be another useful biomarker for the successful treatment with the poly (ADP-ribose) polymerase inhibitor?. 2016 , 1, 3		2
425	Colorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome. 2016 , 6, 252		3

424	Overview of DNA repair pathways, current targets, and clinical trials bench to clinic. 2016 , 1-54	4
423	Natural Polyphenols in Cancer Chemoresistance. 2016 , 68, 879-91	35
422	Inhibition of autophagy enhances effects of PF-04691502 on apoptosis and DNA damage of lung cancer cells. 2016 , 78, 52-62	9
421	Human CDK18 promotes replication stress signaling and genome stability. 2016 , 44, 8772-8785	27
420	Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides. 2016 , 55, 7203-7	113
419	The impact of DNA damage response gene polymorphisms on therapeutic outcomes in late stage ovarian cancer. 2016 , 6, 38142	8
418	Identifying biological mechanisms for favorable cancer prognosis using non-hypothesis-driven iterative survival analysis. 2016 , 2, 16037	3
417	C1D family proteins in coordinating RNA processing, chromosome condensation and DNA damage response. 2016 , 11, 2	8
416	Cancer cell specific cytotoxic effect of Rhoec discolor extracts and solvent fractions. 2016 , 190, 46-58	6
415	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. 2016 , 22, 3132-7	22
414	UV-dependent phosphorylation of COP9/signalosome in UV-induced apoptosis. 2016 , 35, 3101-5	7
413	First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib. 2016 , 11, 3179-3190	73
412	Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. 2016 , 22, 5651-5660	91
411	Targeting deficient DNA damage repair in gastric cancer. 2016 , 17, 1757-66	10
410	Molecular Cell Biology of Apoptosis and Necroptosis in Cancer. 2016 , 930, 1-23	34
409	ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. 2016 , 127, 582-95	154
408	An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy. 2016 , 59, 9575-9598	111
407	Management of Individuals With a Mutation in the Ataxia Telangiectasia Mutated Gene. 2016 , 43, 114-7	1

406	Hyperactivation of ATM upon DNA-PKcs inhibition modulates p53 dynamics and cell fate in response to DNA damage. 2016 , 27, 2360-7		36
405	Emerging targets for radioprotection and radiosensitization in radiotherapy. 2016 , 37, 11589-11609		22
404	DNA repair mechanisms and their clinical impact in glioblastoma. 2016 , 769, 19-35		94
403	Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase. 2016 , 59, 6281-92		43
402	Pharmacological Inhibition of the Protein Kinase MRK/ZAK Radiosensitizes Medulloblastoma. 2016 , 15, 1799-808		4
401	c-Myb regulates NOX1/p38 to control survival of colorectal carcinoma cells. 2016 , 28, 924-36		16
400	ATR inhibition rewires cellular signaling networks induced by replication stress. 2016 , 16, 402-16		18
399	Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides. 2016 , 128, 7319-7323		36
398	Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs. <i>Pharmacology & Therapeutics</i> , 2016 , 162, 69-85	13.9	22
397	Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC. 2016 , 35, 4345-57		24
396	DNA replication stress and cancer: cause or cure?. 2016 , 12, 221-37		28
395	Tetraploidization or autophagy: The ultimate fate of senescent human endometrial stem cells under ATM or p53 inhibition. 2016 , 15, 117-27		14
394	DNA repair targeted therapy: The past or future of cancer treatment?. <i>Pharmacology & Therapeutics</i> , 2016 , 160, 65-83	13.9	233
393	Cancer TARGETases: DSB repair as a pharmacological target. <i>Pharmacology & Therapeutics</i> , 2016 , 161, 111-131	13.9	16
392	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. 2016 , 29, 564-616		112
391	Bim directly antagonizes Bcl-xl in doxorubicin-induced prostate cancer cell apoptosis independently of p53. 2016 , 15, 394-402		20
390	Induction of ROS-independent DNA damage by curcumin leads to G2/M cell cycle arrest and apoptosis in human papillary thyroid carcinoma BCPAP cells. 2016 , 7, 315-25		46
389	Evaluation of [¹⁸ F]-ATRi as PET tracer for in vivo imaging of ATR in mouse models of brain cancer. 2017 , 48, 9-15		3

388	Therapeutic Targeting of RNA Polymerase I With the Small-Molecule CX-5461 for Prevention of Arterial Injury-Induced Neointimal Hyperplasia. 2017 , 37, 476-484	12
387	AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells. 2017 , 16, 566-577	74
386	Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells. 2017 , 232, 3433-3443	11
385	PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. 2017 , 77, 113-130	34
384	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. 2017 , 140, 2587-2595	21
383	Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells. 2017 , 7, 41950	28
382	ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib. 2017 , 10, 190-196	72
381	Sulfoximines as ATR inhibitors: Analogs of VE-821. 2017 , 27, 2659-2662	16
380	Functional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methods. 2017 , 18, 519-533	15
379	Quantitative and Dynamic Imaging of ATM Kinase Activity by Bioluminescence Imaging. 2017 , 1599, 97-111	2
378	An HTRF Assay for the Protein Kinase ATM. 2017 , 1599, 43-56	1
377	Ugi Reaction-Derived β -Acyl Aminocarboxamides Bind to Phosphatidylinositol 3-Kinase-Related Kinases, Inhibit HSF1-Dependent Heat Shock Response, and Induce Apoptosis in Multiple Myeloma Cells. 2017 , 60, 4147-4160	12
376	Synthesis and Profiling of a Novel Potent Selective Inhibitor of CHK1 Kinase Possessing Unusual N-trifluoromethylpyrazole Pharmacophore Resistant to Metabolic N-dealkylation. 2017 , 16, 1831-1842	9
375	Novel tetrahydroacridine and cyclopentaquinoline derivatives with fluorobenzoic acid moiety induce cell cycle arrest and apoptosis in lung cancer cells by activation of DNA damage signaling. 2017 , 39, 1010428317695011	9
374	Achieving Precision Death with Cell-Cycle Inhibitors that Target DNA Replication and Repair. 2017 , 23, 3232-3240	50
373	Chemical screening identifies ATM as a target for alleviating senescence. 2017 , 13, 616-623	85
372	Pancreatic Cancer Genomes: Implications for Clinical Management and Therapeutic Development. 2017 , 23, 1638-1646	92
371	The cell cycle checkpoint inhibitors in the treatment of leukemias. 2017 , 10, 77	35

370	Quantitative and Dynamic Imaging of ATM Kinase Activity. 2017 , 1596, 131-145	2
369	A Study on the Anticarcinogenic Effects of Calcium Fructoborate. 2017 , 178, 210-217	5
368	DNA damage repair in breast cancer and its therapeutic implications. 2017 , 49, 156-165	36
367	ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells. 2017 , 8, 295-319	53
366	DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy. 2017 , 60, 139-151	90
365	Ataxia telangiectasia syndrome: moonlighting ATM. 2017 , 13, 1155-1172	24
364	In Vivo and In Vitro Effects of ATM/ATR Signaling Pathway on Proliferation, Apoptosis, and Radiosensitivity of Nasopharyngeal Carcinoma Cells. 2017 , 32, 193-203	6
363	Potential role of ZEB1 as a DNA repair regulator in colorectal cancer cells revealed by cancer-associated promoter profiling. 2017 , 38, 1941-1948	8
362	Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression. 2017 , 7, 8078	13
361	ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways. 2017 , 8, 241	29
360	CYP-Mediated Sulfoximine Deimination of AZD6738. 2017 , 45, 1133-1138	6
359	Cdc7-Dbf4-mediated phosphorylation of HSP90-S164 stabilizes HSP90-HCLK2-MRN complex to enhance ATR/ATM signaling that overcomes replication stress in cancer. 2017 , 7, 17024	12
358	3.9 Bstructure of the yeast Mec1-Ddc2 complex, a homolog of human ATR-ATRIP. 2017 , 358, 1206-1209	44
357	Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine. 2017 , 7, 15031	6
356	Xeroderma Pigmentosa Group A (XPA), Nucleotide Excision Repair and Regulation by ATR in Response to Ultraviolet Irradiation. 2017 , 996, 41-54	11
355	Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy. 2017 , 124, 475-481	20
354	Simultaneous targeting of ATM and Mcl-1 increases cisplatin sensitivity of cisplatin-resistant non-small cell lung cancer. 2017 , 18, 606-615	13
353	Mechanisms of resistance of chemotherapy in early-stage triple negative breast cancer (TNBC). 2017 , 34 Suppl 1, S27-S30	64

352	Adaptive mechanisms of resistance to anti-neoplastic agents. 2017 , 8, 53-66	11
351	Genomic complexity of multiple myeloma and its clinical implications. 2017 , 14, 100-113	267
350	Novel betulin derivative induces anti-proliferative activity by G/M phase cell cycle arrest and apoptosis in Huh7 cells. 2018 , 15, 2097-2104	8
349	TTT and PIKK Complex Genes Reverted to Single Copy Following Polyploidization and Retain Function Despite Massive Retrotransposition in Maize. 2017 , 8, 1723	3
348	Human Papillomavirus and the DNA Damage Response: Exploiting Host Repair Pathways for Viral Replication. 2017 , 9,	38
347	The Dual Roles of MYC in Genomic Instability and Cancer Chemoresistance. 2017 , 8,	22
346	Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. 2017 , 37, 3377-3386	15
345	Association between ATM gene polymorphisms, lung cancer susceptibility and radiation-induced pneumonitis: a meta-analysis. 2017 , 17, 205	13
344	Identification of a novel ATM inhibitor with cancer cell specific radiosensitization activity. 2017 , 8, 73925-73937	14
343	Selective Kinase Inhibitors in Cancer. 2017 , 39-75	3
342	Targeting DNA Damage Response Pathways in Cancer. 2017 , 104-133	
341	Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. 2017 , 37, 246-256	13
340	Cholesterol overload in the liver aggravates oxidative stress-mediated DNA damage and accelerates hepatocarcinogenesis. 2017 , 8, 104136-104148	26
339	DNA Damage: Cellular Responses, Repair, and Cancer Treatment. 2018 , 99-127	0
338	Regulation of Signal Transduction in Human Cell Research. 2018 ,	
337	The clinical significance of PD-L1 in advanced gastric cancer is dependent on mutations and ATM expression. 2018 , 7, e1457602	6
336	Effects of Aptamer to U87-EGFRvIII Cells on the Proliferation, Radiosensitivity, and Radiotherapy of Glioblastoma Cells. 2018 , 10, 438-449	20
335	Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair. 2018 , 39, 912-920	20

334	ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. 2018 , 9, 57	54
333	ATM and ATR play complementary roles in the behavior of excitatory and inhibitory vesicle populations. 2018 , 115, E292-E301	23
332	Precision Medicine Based on Next-Generation Sequencing and Master Controllers. 2018 , 1577-1611	0
331	Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. 2018 , 1613-1641	1
330	Targeting cell cycle dependencies represent a novel therapeutic approach for selected sarcoma subgroups. 2018 , 29, 798-799	
329	ATR/CHK1 inhibitors and cancer therapy. 2018 , 126, 450-464	126
328	Cellular Responses to DNA Damage. 2018 , 498-529	
327	Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. 2018 , 24, 351-359	60
326	A novel morphometry system automatically assessing the growth and regeneration of intestinal organoids. 2018 , 506, 1052-1058	4
325	Cell type-dependent bimodal p53 activation engenders a dynamic mechanism of chemoresistance. 2018 , 4, eaat5077	17
324	Temporal DNA-PK activation drives genomic instability and therapy resistance in glioma stem cells. 2018 , 3,	29
323	RNA interference to enhance radiation therapy: Targeting the DNA damage response. 2018 , 439, 14-23	7
322	Hypoxia and Selective Autophagy in Cancer Development and Therapy. 2018 , 6, 104	88
321	The intracellular signalosome of PD-L1 in cancer cells. 2018 , 3, 26	108
320	Selective human inhibitors of ATR and ATM render <i>Leishmania major</i> promastigotes sensitive to oxidative damage. 2018 , 13, e0205033	6
319	Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. 2018 , 24, 3393-3403.e5	12
318	Evaluation of Maltose Binding Protein-Tagged hATR Kinase Domain Catalytic Activity with p53 Ser-15 Phosphorylation. 2018 , 57, 6592-6603	
317	Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. 2018 , 61, 9889-9907	125

316	P53 enhances apoptosis induced by doxorubicin only under conditions of severe DNA damage. 2018 , 17, 2175-2186	16
315	Inhibition of ATR acutely sensitizes acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase. 2018 , 2, 1157-1169	16
314	Pre-clinical Profile and Expectations for Pharmacological ATM Inhibition. 2018 , 155-183	
313	Targeting ATM for Cancer Therapy: Prospects for Drugging ATM. 2018 , 185-208	1
312	The role of p38 MAPK pathway in p53 compromised state and telomere mediated DNA damage response. 2018 , 836, 89-97	12
311	Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies. 2018 , 2018, 2389523	60
310	ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells. 2018 , 46, 8311-8325	29
309	Advances in Glioblastoma Multiforme Treatment: New Models for Nanoparticle Therapy. 2018 , 9, 170	81
308	Synaptotagmin7 Is Overexpressed In Colorectal Cancer And Regulates Colorectal Cancer Cell Proliferation. 2018 , 9, 2349-2356	13
307	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. 2018 , 10,	14
306	Clinically Applicable Inhibitors Impacting Genome Stability. 2018 , 23,	10
305	Discovery of a Series of 3-Cinnoline Carboxamides as Orally Bioavailable, Highly Potent, and Selective ATM Inhibitors. 2018 , 9, 809-814	11
304	Remarkable response to a novel ATR inhibitor in a patient with poorly differentiated neuroendocrine carcinoma. 2018 , 16, 9-12	3
303	ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration. 2018 , 13, 76	21
302	Induction of p53 Phosphorylation at Serine 20 by Resveratrol Is Required to Activate p53 Target Genes, Restoring Apoptosis in MCF-7 Cells Resistant to Cisplatin. 2018 , 10,	12
301	Zearalenone Exposure Enhanced the Expression of Tumorigenesis Genes in Donkey Granulosa Cells via the // Signaling Pathway. 2018 , 9, 293	12
300	Predicting Disease Genes from Clinical Single Sample-Based PPI Networks. 2018 , 247-258	2
299	The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. 2018 , 432, 56-68	28

298	Differentiation of sow and mouse ovarian granulosa cells exposed to zearalenone in vitro using RNA-seq gene expression. 2018 , 350, 78-90	8
297	Advances in targeted alpha therapy for prostate cancer. 2019 , 30, 1728-1739	26
296	Zika Virus Infection Induces DNA Damage Response in Human Neural Progenitors That Enhances Viral Replication. 2019 , 93,	20
295	ATM in DNA repair in cancer. <i>Pharmacology & Therapeutics</i> , 2019 , 203, 107391	13.9 68
294	DNA-Repair Gene Mutations Are Highly Prevalent in Circulating Tumour DNA from Multiple Myeloma Patients. 2019 , 11,	8
293	ATR function is indispensable to allow proper mammalian follicle development. 2019 , 128, 489-500	4
292	Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344. 2019 , 105, 410-422	9
291	Dissecting the molecular landscape of pancreatic cancer: towards a precision medicine approach. 2019 , 4, 113-119	3
290	BDE-209 induces male reproductive toxicity via cell cycle arrest and apoptosis mediated by DNA damage response signaling pathways. 2019 , 255, 113097	17
289	Tissue-Specific Chk1 Activation Determines Apoptosis by Regulating the Balance of p53 and p21. 2019 , 12, 27-40	6
288	Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death. 2019 , 8, 38	33
287	Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer. 2019 , 167, 163-172	10
286	ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation. 2019 , 10, 459	23
285	Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor. 2019 , 62, 5547-5561	18
284	Structural basis of allosteric regulation of Tel1/ATR kinase. 2019 , 29, 655-665	15
283	IL-6 signaling contributes to radioresistance of prostate cancer through key DNA repair-associated molecules ATM, ATR, and BRCA 1/2. 2019 , 145, 1471-1484	8
282	Evaluation of ATM Kinase Inhibitor KU-55933 as Potential Anti- Agent. 2019 , 9, 26	15
281	Somatic genome alterations in relation to age in lung adenocarcinoma. 2019 , 145, 2091-2099	0

280	Phosphorylation of proliferating cell nuclear antigen promotes cancer progression by activating the ATM/Akt/GSK3 β /Snail signaling pathway. 2019 , 294, 7037-7045	13
279	DNA Repair Gene Expression Adjusted by the Metagene Predicts Survival in Multiple Cancers. 2019 , 11,	1
278	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. 2019 , 12, 38	38
277	Revealing quinquennial anticancer journey of morpholine: A SAR based review. 2019 , 167, 324-356	44
276	MRN (MRE11-RAD50-NBS1) Complex in Human Cancer and Prognostic Implications in Colorectal Cancer. 2019 , 20,	27
275	Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. 2019 , 294, 5700-5719	11
274	Viral replication centers and the DNA damage response in JC virus-infected cells. 2019 , 528, 198-206	11
273	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. 2019 , 4, 11-25	1
272	Pesticide mediated oxidative stress induces genotoxicity and disrupts chromatin structure in fenugreek (<i>Trigonella foenum - graecum</i> L.) seedlings. 2019 , 369, 362-374	23
271	Diversity of the Senescence Phenotype of Cancer Cells Treated with Chemotherapeutic Agents. 2019 , 8,	38
270	Molecular biomarkers of DNA damage in diffuse large-cell lymphoma— review. 2019 , 4, 5-5	3
269	IL-24 Inhibits Lung Cancer Growth by Suppressing GLI1 and Inducing DNA Damage. 2019 , 11,	6
268	APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. 2019 , 21, 1143-1150	25
267	Anti-Tumor Effect of Inhibition of DNA Damage Response Proteins, ATM and ATR, in Endometrial Cancer Cells. 2019 , 11,	13
266	Emerging Translational Opportunities in Comparative Oncology With Companion Canine Cancers: Radiation Oncology. 2019 , 9, 1291	11
265	Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response. 2019 , 10,	68
264	State-of-the-art strategies for targeting the DNA damage response in cancer. 2019 , 16, 81-104	412
263	Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer. 2020 , 61, 437-442	6

262	Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G DNA Damage Checkpoint. 2020 , 19, 123-134	12
261	Targeting the DNA damage response (DDR) by natural compounds. 2020 , 28, 115279	9
260	Synthetic lethality: a step forward for personalized medicine in cancer. 2020 , 25, 305-320	10
259	Therapeutic Potential of the miRNA-ATM Axis in the Management of Tumor Radioresistance. 2020 , 80, 139-150	13
258	Recent advancements in PARP inhibitors-based targeted cancer therapy. 2020 , 3, 187-201	14
257	KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. 2020 , 31, 1746-1754	58
256	Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma. 2020 , 12, 1758835920956900	6
255	ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells. 2020 , 6, e05097	2
254	Characterization of SPK 98, a Torin2 analog, as ATR and mTOR dual kinase inhibitor. 2020 , 30, 127517	1
253	CircATP2B4 promotes hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells via the miR-223/ATR axis. 2020 , 262, 118420	4
252	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. 2020 , 31, 1135-1147	27
251	deficiency-associated heterochromatin induces intrinsic DNA replication stress and susceptibility to ATR inhibition in lung adenocarcinoma. 2020 , 2, zcaa005	10
250	Investigating the Benefit of Combined Androgen Modulation and Hypofractionation in Prostate Cancer. 2020 , 21,	
249	Molecular characteristics of and mutations in pancreatic ductal adenocarcinoma. 2020 , 5, e000942	11
248	Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology. 2020 , 21,	11
247	Editorial: Exploiting DNA Damage Response in the Era of Precision Oncology. 2020 , 10, 611127	
246	Phospho-Ser-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. 2020 , 31, 107745	4
245	ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data. 2020 , 15, 184	3

244	Targeting DNA Repair Pathways in Hematological Malignancies. 2020 , 21,	3
243	CHK1 Inhibitor Blocks Phosphorylation of FAM122A and Promotes Replication Stress. 2020 , 80, 410-422.e6	11
242	Discovery and development of novel DNA-PK inhibitors by targeting the unique Ku-DNA interaction. 2020 , 48, 11536-11550	13
241	Partners in crime: POPX2 phosphatase and its interacting proteins in cancer. 2020 , 11, 840	1
240	ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment. 2020 , 11, 933	16
239	Chemical Inhibitors of a Selective SWI/SNF Function Synergize with ATR Inhibition in Cancer Cell Killing. 2020 , 15, 1685-1696	3
238	ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status. 2020 , 10, 7488	5
237	A critical role of telomere chromatin compaction in ALT tumor cell growth. 2020 , 48, 6019-6031	1
236	Clinical and functional significance of tumor/stromal ATR expression in breast cancer patients. 2020 , 22, 49	1
235	Novel therapeutic strategies for MLL-rearranged leukemias. 2020 , 1863, 194584	1
234	The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe. 2020 , 14, 2487-2503	7
233	Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. 2020 , 63, 7293-7325	13
232	Differential activation of eMI by distinct forms of cellular stress. 2021 , 17, 1828-1840	9
231	DNA damage checkpoint kinases in cancer. 2020 , 22, e2	49
230	Checkpoint Responses to DNA Double-Strand Breaks. 2020 , 89, 103-133	28
229	Withania somnifera (L.) Dunal: A potential therapeutic adjuvant in cancer. 2020 , 255, 112759	16
228	Adefovir dipivoxil induces DNA replication stress and augments ATR inhibitor-related cytotoxicity. 2020 , 147, 1474-1484	2
227	Pharmacological inhibition of ataxia-telangiectasia mutated exacerbates acute kidney injury by activating p53 signaling in mice. 2020 , 10, 4441	7

226	Synthesis and Biological Evaluations of Monocarbonyl Curcumin Inspired Pyrazole Analogues as Potential Anti-Colon Cancer Agent. 2020 , 14, 2517-2534	3
225	Augmenting the therapeutic window of radiotherapy: A perspective on molecularly targeted therapies and nanomaterials. 2020 , 150, 225-235	4
224	Emerging precision therapies for gastric cancer. 2020 , 5, 299-311	1
223	Identification of GSN and LAMC2 as Key Prognostic Genes of Bladder Cancer by Integrated Bioinformatics Analysis. 2020 , 12,	10
222	DNA damage response proteins regulating mitotic cell division: double agents preserving genome stability. 2020 , 287, 1700-1721	22
221	Isoquinoline thiosemicarbazone displays potent anticancer activity with efficacy against aggressive leukemias. 2020 , 11, 392-410	4
220	Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. <i>Pharmacology & Therapeutics</i> , 2020 , 210, 107518	13.9 30
219	Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma. 2020 , 99, e18823	4
218	DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. 2020 , 5, 60	157
217	Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. 2020 , 10, 371	10
216	Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer. 2020 , 13, 39	22
215	NUSAP1 potentiates chemoresistance in glioblastoma through its SAP domain to stabilize ATR. 2020 , 5, 44	19
214	Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. 2021 , 168, 158-180	41
213	Mechanism of auto-inhibition and activation of Mec1 checkpoint kinase. 2021 , 28, 50-61	9
212	Reality CHEK: Understanding the biology and clinical potential of CHK1. 2021 , 497, 202-211	22
211	First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. 2021 , 11, 80-91	45
210	Roles of ATM and ATR in DNA double strand breaks and replication stress. 2021 , 161, 27-38	6
209	The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors. 2021 , 27, 937-962	5

208	DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy. 2021 , 252-253, 6-24	9
207	Cancer-associated mutations in the condensin II subunit CAPH2 cause genomic instability through telomere dysfunction and anaphase chromosome bridges. 2021 , 236, 3579-3598	3
206	The Interactions of DNA Repair, Telomere Homeostasis, and p53 Mutational Status in Solid Cancers: Risk, Prognosis, and Prediction. 2021 , 13,	3
205	Proteins Involved in Colorectal Cancer: Identification Strategies and Possible Roles. 2021 , 179-194	
204	Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy. 2021 , 4, 244-263	4
203	Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. 2021 , 27, 100328	33
202	Mitotic syndicates Aurora Kinase B (AURKB) and mitotic arrest deficient 2 like 2 (MAD2L2) in cohorts of DNA damage response (DDR) and tumorigenesis. 2021 , 787, 108376	6
201	Intratumoral heterogeneity associated with glioblastoma drug response and resistance. 2021 , 185-199	
200	DNA double-strand break repair in cancer: A path to achieving precision medicine. 2021 , 364, 111-137	6
199	The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells. 2021 , 73, 40-51	2
198	The ATM and ATR kinases regulate centrosome clustering and tumor recurrence by targeting KIFC1 phosphorylation. 2021 , 12, 20	11
197	Progress towards a clinically-successful ATR inhibitor for cancer therapy.. 2021 , 2, 100017	14
196	Role of Non-coding RNAs on the Radiotherapy Sensitivity and Resistance of Head and Neck Cancer: From Basic Research to Clinical Application. 2020 , 8, 637435	1
195	Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers. 2021 , 22,	6
194	Cooperative Blockade of CK2 and ATM Kinases Drives Apoptosis in VHL-Deficient Renal Carcinoma Cells through ROS Overproduction. 2021 , 13,	3
193	The Role of Intrinsic Signaling Pathways in Cell Proliferation. 2021 , 11, 2030003	1
192	It takes three to the DNA damage response tango. 2021 , 8, 1881395	0
191	DNA Repair Pathways in Cancer Therapy and Resistance. 2020 , 11, 629266	40

190	Clinical-grade whole-genome sequencing and 3' transcriptome analysis of colorectal cancer patients. 2021 , 13, 33	2
189	Regulation of cardiomyocyte DNA damage and cell death by the type 2A protein phosphatase regulatory protein alpha4. 2021 , 11, 6293	
188	Effect of Reducing Ataxia-Telangiectasia Mutated (ATM) in Experimental Autosomal Dominant Polycystic Kidney Disease. 2021 , 10,	0
187	Phosphorylation state of the histone variant H2A.X controls human stem and progenitor cell fate decisions. 2021 , 34, 108818	2
186	Exploring the Roles of HERC2 and the NEDD4L HECT E3 Ubiquitin Ligase Subfamily in p53 Signaling and the DNA Damage Response. 2021 , 11, 659049	3
185	Natural products targeting into cancer hallmarks: An update on caffeine, theobromine, and (+)-catechin. 2021 , 1-20	6
184	Molecular Docking and Molecular Dynamics Simulation Studies of Quinoline-3-Carboxamide Derivatives with DDR Kinases Selectivity Studies towards ATM Kinase. 2021 , 3, 511-524	
183	Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy. 2021 , 28, 963-985	4
182	Zebrafish Cancer Predisposition Models. 2021 , 9, 660069	4
181	Phosphopeptide interactions of the Nbs1 N-terminal FHA-BRCT1/2 domains. 2021 , 11, 9046	2
180	The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors solve the problem?. 2021 , 101, 103074	4
179	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine + cisplatin in patients with advanced solid tumours. 2021 , 125, 510-519	16
178	Comparative analyses of aging-related genes in long-lived mammals provide insights into natural longevity. 2021 , 2, 100108	2
177	LARP7 Protects Against Heart Failure by Enhancing Mitochondrial Biogenesis. 2021 , 143, 2007-2022	8
176	miR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC. 2021 , 13, e12872	5
175	Targeted Treatment of Head and Neck (Pre)Cancer: Preclinical Target Identification and Development of Novel Therapeutic Applications. 2021 , 13,	2
174	The Atr-Chek1 pathway inhibits axon regeneration in response to Piezo-dependent mechanosensation. 2021 , 12, 3845	4
173	Kinase Inhibitors of DNA-PK, ATM and ATR in Combination with Ionizing Radiation Can Increase Tumor Cell Death in HNSCC Cells While Sparing Normal Tissue Cells. 2021 , 12,	3

172	Ataxia telangiectasia mutated inhibitor-loaded copper sulfide nanoparticles for low-temperature photothermal therapy of hepatocellular carcinoma. 2021 , 127, 276-286	9
171	An Overview of the Recent Development of Anticancer Agents Targeting the HIF-1 Transcription Factor. 2021 , 13,	10
170	Sensors and Inhibitors for the Detection of Ataxia Telangiectasia Mutated (ATM) Protein Kinase. 2021 , 18, 2470-2481	1
169	Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study. 2021 ,	8
168	Molecular Pathways and Druggable Targets in Head and Neck Squamous Cell Carcinoma. 2021 , 13,	3
167	Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target. 2021 , 13,	1
166	Gene network analysis to determine the effect of hypoxia-associated genes on brain damages and tumorigenesis using an avian model. 2021 , 19, 100	
165	Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer. 2021 , 36, 109394	9
164	Roles of ATM and ATR in DNA double strand breaks and replication stress. 2021 , 163, 109-119	3
163	Increased DNA repair capacity augments resistance of glioblastoma cells to photodynamic therapy. 2021 , 104, 103136	6
162	Novel Insights into the Molecular Regulation of Ribonucleotide Reductase in Adrenocortical Carcinoma Treatment. 2021 , 13,	3
161	Mechanisms of Cancer Cell Death: Therapeutic Implications for Pancreatic Ductal Adenocarcinoma. 2021 , 13,	2
160	Molecular basis of human ATM kinase inhibition. 2021 , 28, 789-798	3
159	Drug Repurposing for Targeting Acute Leukemia With ()-Gene Rearrangements. 2021 , 12, 741413	0
158	Periodontal Pathogens Promote Oral Squamous Cell Carcinoma by Regulating ATR and NLRP3 Inflammasome. 2021 , 11, 722797	6
157	Synthetic lethality theory approaches to effective substance discovery and functional mechanisms elucidation of anti-cancer phytomedicine. 2021 , 91, 153718	1
156	R-loop modulated epigenetic regulation in T helper cells mechanistically associates coronary artery disease and non-small cell lung cancer. 2021 , 14, 101189	0
155	Inhibition of the DSB repair protein RAD51 potentiates the cytotoxic efficacy of doxorubicin via promoting apoptosis-related death pathways. 2021 , 520, 361-373	2

154	New and Promising Targeted Therapies in First and Second-Line Settings. 2021 , 277-296	
153	Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. 2020 , 10, 22087	6
152	Directing the use of DDR kinase inhibitors in cancer treatment. 2017 , 26, 1341-1355	57
151	Variable sensitivity to DNA damaging chemotherapeutic modulated by cell type-dependent bimodal p53 dynamics.	1
150	DNA Repair Gene Expression Adjusted by the PCNA Metagene Predicts Survival in Multiple Cancers.	1
149	ATR function is indispensable to allow proper mammalian follicle development.	0
148	Inhibition of a Selective SWI/SNF Function Synergizes with ATR Inhibitors in Cancer Cell Killing.	2
147	ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer. 2020 , 12, 1758835920982853	5
146	The G2 checkpoint inhibitor CBP-93872 increases the sensitivity of colorectal and pancreatic cancer cells to chemotherapy. 2017 , 12, e0178221	7
145	Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors. 2018 , 13, e0194790	2
144	The Adenovirus E4orf4 Protein Provides a Novel Mechanism for Inhibition of the DNA Damage Response. 2016 , 12, e1005420	16
143	Alleviation of Senescence via ATM Inhibition in Accelerated Aging Models. 2019 , 42, 210-217	13
142	Phosphoproteomics reveals novel modes of function and inter-relationships among PIKKs in response to genotoxic stress. 2021 , 40, e104400	14
141	Nucleolar stress induces a senescence-like phenotype in smooth muscle cells and promotes development of vascular degeneration. 2020 , 12, 22174-22198	5
140	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. 2016 , 7, 49800-49818	62
139	Millepachine, a potential topoisomerase II inhibitor induces apoptosis via activation of NF-B pathway in ovarian cancer. 2016 , 7, 52281-52293	13
138	Phosphatidylinositide 3-kinase (PI3K) and PI3K-related kinase (PIKK) activity contributes to radioresistance in thyroid carcinomas. 2016 , 7, 63106-63123	9
137	PICT-1 is a key nucleolar sensor in DNA damage response signaling that regulates apoptosis through the RPL11-MDM2-p53 pathway. 2016 , 7, 83241-83257	11

136	Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks. 2017 , 8, 22662-22673	18
135	ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. 2017 , 8, 17164-17190	17
134	Germline mutations in pancreatic cancer and potential new therapeutic options. 2017 , 8, 73240-73257	33
133	MicroRNA16 regulates glioma cell proliferation, apoptosis and invasion by targeting Wip1-ATM-p53 feedback loop. 2017 , 8, 54788-54798	22
132	Studies of lncRNAs in DNA double strand break repair: what is new?. 2017 , 8, 102690-102704	6
131	ATR suppresses the pro-tumorigenic functions of breast stromal fibroblasts. 2018 , 9, 34681-34690	3
130	Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and irradiation in human glioblastoma cells. 2019 , 10, 825-846	14
129	Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer. 2019 , 10, 6981-6996	5
128	Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. 2015 , 6, 32396-409	43
127	A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers. 2016 , 7, 7080-95	32
126	Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. 2016 , 7, 25885-901	17
125	Translational research in radiation-induced DNA damage signaling and repair. 2017 , 6, S875-S891	29
124	Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. 2017 , 24, 1586-1606	61
123	Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment. 2019 , 26, 1425-1445	6
122	Synthesis and Characterization of Quinoline-3-Carboxamide Derivatives as Inhibitors of the ATM Kinase. 2020 , 20, 2070-2079	1
121	Next-Generation Sequencing Approaches in Cancer: Where Have They Brought Us and Where Will They Take Us?. 2015 , 7, 1925-58	40
120	Japanese apricot extract (MK615) potentiates bendamustine-induced apoptosis via impairment of the DNA damage response in lymphoma cells. 2017 , 14, 792-800	7
119	Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer. 2019 , 51, 1167-1179	14

118	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. 2021 , 163, 246-253	8
117	A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients. 2021 ,	1
116	CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery. 2021 ,	3
115	A pleiotropic ATM variant (rs1800057 C>G) is associated with risk of multiple cancers. 2021 ,	0
114	Emerging Therapeutic Targets in Pancreatic Adenocarcinoma. 2016 , 1-29	
113	CHROMATIN STRUCTURE AND DNA DAMAGE RESPONSE. 2017 , 19, 120-124	0
112	Precision Medicine Based on Next Generation Sequencing and Master Controllers. 2018 , 1-35	
111	Molecular Diagnostics and Genomic Profiling in Individualized Therapies of Gastrointestinal Cancers. 2019 , 613-631	
110	ATM Inhibition Synergizes with Fenofibrate in High Grade Serous Ovarian Cancer Cells.	
109	Clinical-grade whole genome sequencing of colorectal cancer and 3 β transcriptome analysis demonstrate targetable alterations in the majority of patients.	
108	The Atr-Chek1 pathway inhibits axon regeneration in response to Piezo-dependent mechanosensation.	
107	The RECQL helicase prevents replication fork collapse during replication stress. 2020 , 3,	0
106	Discovery and Development of Novel DNA-PK Inhibitors by Targeting the unique Ku-DNA Interaction.	1
105	PARP5B is required for nonhomologous end joining during tumorigenesis in vivo. 2022 , 61, 85-98	2
104	Target-Based Radiosensitization Strategies: Concepts and Companion Animal Model Outlook. 2021 , 11, 768692	2
103	In vitro evaluation of the effect of the electronic cigarette aerosol, Cannabis smoke, and conventional cigarette smoke on the properties of gingival fibroblasts/gingival mesenchymal stem cells. 2021 ,	1
102	The importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. 2021 , 1-13	5
101	HMGA2 gene silencing reduces epithelial-mesenchymal transition and lymph node metastasis in cervical cancer through inhibiting the ATR/Chk1 signaling pathway. 2018 , 10, 3036-3052	10

100	Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology. 2022 , 32, 42-53	1
99	Chlorin e6 mediated photodynamic therapy triggers resistance through ATM-related DNA damage response in lung cancer cells. 2021 , 102645	4
98	MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistance. 2021 , 12, 1111	2
97	ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. 2021 , 12, 6813	0
96	The cytosolic iron-sulfur cluster assembly (CIA) pathway is required for replication stress tolerance of cancer cells to Chk1 and ATR inhibitors. 2021 , 7, 152	0
95	Comprehensively investigating the expression levels and the prognostic role of transforming growth factor beta-induced (TGFBI) in glioblastoma multiforme.. 2020 , 9, 6487-6504	1
94	The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance.. 2021 , 27, 491-500	0
93	Nucleotide imbalance decouples cell growth from cell proliferation.	1
92	HJURP Promotes Malignant Progression and Mediates Sensitivity to Cisplatin and WEE1-inhibitor in Serous Ovarian Cancer.. 2022 , 18, 1188-1210	0
91	Ataxia-Telangiectasia (Louis-Bar Syndrome). 2022 , 97-104	
90	Theranostic Interpolation of Genomic Instability in Breast Cancer.. 2022 , 23,	0
89	Selinexor as Novel Inhibitor of DNA Damage Response in Merkel Cell Carcinoma.. 2022 ,	0
88	Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.. 2022 , 1	2
87	Research Progress of ATR Inhibitors in Anti-Tumor. 2022 , 11, 113-126	
86	Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes.. 2022 , 14, 17588359221083050	3
85	A clinically relevant heterozygous ATR mutation sensitizes colorectal cancer cells to replication stress.. 2022 , 12, 5422	2
84	Sweet Wormwood and Tortoise Shell Decoction (Thanh Hao Miet Giap Thang) Induces DNA Damage, S-Phase Arrest, and Apoptosis in MCF-7 Cells via ATR-CHK1 Signaling Pathway.. 2022 , 2022, 2358290	
83	Positive regulation of ataxia-telangiectasia-mutated protein (ATM) by E2F transcription Factor 1 (E2F-1) in cisplatin-resistant nasopharyngeal carcinoma cells.. 2022 , 20, 88	

82	Osmotic Stress Interferes with DNA Damage Response and H2AX Phosphorylation in Human Keratinocytes.. 2022 , 11,	
81	Targeting the DNA Damage Response to Increase Anthracycline-Based Chemotherapy Cytotoxicity in T-Cell Lymphoma.. 2022 , 23,	
80	Testis-specific hnRNP is expressed in colorectal cancer cells and accelerates cell growth mediating ZDHHC11 mRNA stabilization.. 2022 ,	0
79	Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma.. 2022 , 14,	0
78	Discovery of 6,7-dihydro-5H-pyrrolo[3,4-d] pyrimidine derivatives as a new class of ATR inhibitors.. 2022 , 128651	0
77	Role and regulation of autophagy in cancer.. 2022 , 166400	3
76	RNR-R2 Upregulation by a Short Non-Coding Viral Transcript.. 2021 , 11,	0
75	Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis.. 2021 , 37, 110146	0
74	Insilico and Invitro optimization of Naringin and rutin molecules targeting DNA damage in breast cancer cells.	
73	Oscillatory dynamics of p53 pathway in etoposide sensitive and resistant cell lines. 2022 , 30, 2075-2108	
72	Quercetin attenuates the proliferation of arsenic-related lung cancer cells via a caspase-dependent DNA damage signaling.. 2022 ,	2
71	A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies.. 2022 ,	1
70	Image_1.jpeg. 2018 ,	
69	Image_2.jpeg. 2018 ,	
68	Image_3.jpeg. 2018 ,	
67	Table_1.docx. 2018 ,	
66	Image_1.PDF. 2020 ,	
65	Image_2.PDF. 2020 ,	

64 Image_3.PDF. 2020,

63 Table_1.xlsx. 2020,

62 Table_2.docx. 2020,

61 Image_1.pdf. 2019,

60 Image_2.tif. 2019,

59 Image_3.tif. 2019,

58 Image_4.tif. 2019,

57 DataSheet1.DOCX. 2018,

56 Targeting DNA damage response in cardiovascular diseases: from pathophysiology to therapeutic implications.. 2022, ○

55 Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment.. 2022, 11, ○

54 Emerging small-molecule inhibitors of ATM kinase targeting cancer therapy. 2022, 179-198

53 Ataxia-telangiectasia mutated and ataxia telangiectasia and Rad3-related kinases as therapeutic targets and stratification indicators for prostate cancer. 2022, 147, 106230 ○

52 Targeting Mechanisms of the DNA Damage Response (DDR) and DNA Repair by Natural Compounds to Improve cAT-Triggered Tumor Cell Death. 2022, 27, 3567 ○

51 Genomic biomarkers to guide precision radiotherapy in prostate cancer. 2022, 82, ○

50 Iodonitrene: A Direct Metal-free Electrophilic Aminating Reagent. 1

49 Genetic variations affecting response of radiotherapy. 2022, 19, 1-6

48 Shared Genetic Risk Factors Between Cancer and Cardiovascular Diseases. 9,

47 The molecular landscape of pancreatic ductal adenocarcinoma. 2022, ○

- 46 Transcriptional landscapes and signaling pathways of chloroquine-treated Esophageal squamous cell carcinoma.
- 45 PLX038: a long-acting topoisomerase I inhibitor with robust anti-tumor activity in ATM deficient tumors and potent synergy with PARP inhibitors.
- 44 T cell-mediated additive cytotoxicity \square Death by multiple bullets. **2022**, ○
- 43 The FBXO32/ATR/ATM axis acts as a molecular switch to control the sensitivity of osteosarcoma cells to irradiation through its regulation of EXO1 expression.
- 42 Nucleotide imbalance decouples cell growth from cell proliferation. **2022**, 24, 1252-1264 1
- 41 Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent. **2022**, 12,
- 40 CNS distribution of the ATM inhibitor AZD1390: Implications for the treatment of brain tumors. JPET-AR-2022-001230
- 39 Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. 12, ○
- 38 Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy. 12, ○
- 37 Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers. **2022**, 11, 3068 ○
- 36 The DNA damage checkpoint: A tale from budding yeast. 13, ○
- 35 Targeting the DNA damage response in pediatric malignancies. 1-15 ○
- 34 Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy. **2022**, 10, e005020 ○
- 33 DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. 1
- 32 Role of genetic variations of DNA damage response pathway genes and heat-shock proteins in increased head and neck cancer risk. ○
- 31 Impact of Alpha-Radiotherapy on the Tumor Microenvironment. **2022**, 1-24 ○
- 30 ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. **2022**, 22, 1
- 29 Resveratrol Enhances the Radiosensitivity by Inducing DNA Damage and Antitumor Immunity in a Glioblastoma Rat Model under 3 T MRI Monitoring. **2022**, 2022, 1-13 1

28	Manipulation of Redox Metabolism using Pharmacologic Ascorbate Opens a Therapeutic Window for Radio-sensitization by ATM Inhibitors in Colorectal Cancer. 2022,	0
27	Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. 2022, 14, 4874	1
26	Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy. 2022, 155, 113797	0
25	ATR inhibition in Advanced Urothelial Carcinoma. 2022,	0
24	ATM inhibition drives metabolic adaptation via induction of macropinocytosis. 2023, 222,	2
23	Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor. 2023, 169, 98-105	0
22	Emerging role of aging in the progression of NAFLD to HCC. 2023, 84, 101833	2
21	Recent advances in ATM inhibitors as potential therapeutic agents.	0
20	Predicting tumour radiosensitivity to deliver precision radiotherapy.	1
19	Ring finger protein 126 promotes breast cancer metastasis and serves as a potential target to improve the therapeutic sensitivity of ATR inhibitors. 2022, 24,	0
18	ATM inhibitor KU60019 synergistically sensitizes lung cancer cells to topoisomerase II poisons by multiple mechanisms. 2023, 13,	0
17	SIRT1 deacetylates WEE1 and sensitizes cancer cells to WEE1 inhibition.	1
16	Exploring pradimicin-IRD antineoplastic mechanisms and related DNA repair pathways. 2023, 371, 110342	0
15	Exposure to Benzo(a)pyrene promotes proliferation and inhibits differentiation of stromal cells in mice during decidualization. 2023, 251, 114531	0
14	Sensitization of cervical cancer cells to radiation by the cyclin-dependent kinase inhibitor dinaciclib. 2023, 40,	0
13	KuDNA binding inhibitors modulate the DNA damage response in response to DNA double-strand breaks. 2023, 5,	0
12	Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy. 2023, 1878, 188866	0
11	Exploring SPK98 for the Selective Sensitization of ATM- or P53-Deficient Cancer Cells. 2023, 8, 4954-4962	0

- 10 DNA Damage and Its Role in Cancer Therapeutics. **2023**, 24, 4741
- 9 ATM-SPARK: A GFP phase separationBased activity reporter of ATM. **2023**, 9,
- 8 IN SILICO LIBRARY SCREENING TO FIND NOVEL ANTICANCER AGENT WITH CHEMOSENSITIZING PROPERTIES: FOCUS ON TARGETING ATAXIA TELANGIECTASIA AND Rad3 RELATED KINASE.
- 7 Association of variations in the CAT and prognosis in lung cancer patients with platinum-based chemotherapy. 14,
- 6 Inclusion of Nitrofurantoin into the Realm of Cancer Chemotherapy via Biology-Oriented Synthesis and Drug Repurposing. **2023**, 66, 4565-4587
- 5 Molecular events leading to CX-5461-induced DNA damage response in vascular smooth muscle cells.
- 4 DNA Repair Mechanisms as a New Target in Head and Neck Cancer. **2023**, 23-35
- 3 Checkpoint Kinase 1 Is a Key Signal Transducer of DNA Damage in the Early Mammalian Cleavage Embryo. **2023**, 24, 6778
- 2 Design, synthesis, and biological evaluation of pyrido[3,2-d]pyrimidine derivatives as novel ATR inhibitors. **2023**, 136, 106535
- 1 CHAF1A promotes the translesion DNA synthesis pathway in response to DNA replication stress.